The Medical Letter publishes critical appraisals of new prescription drugs and comparative reviews of previously approved drugs in its newsletters The Medical Letter on Drugs and Therapeutics and Treatment Guidelines from The Medical Letter.
The Medical Letter relies on a consensus of experts to evaluate drug facts in order to help prescribers choose the most effective drug treatment. The Medical Letter and Treatment Guidelines are crucial resources for unbiased and objective drug information and are completely independent of pharmaceutical industry influence.
What does The Medical Letter app include?
The Medical Letter on Drugs and Therapeutics: Subscribers to The Medical Letter get full access to their paid subscription content with this free app and can take free CME/CE directly from their mobile device to earn up to 26 AMA PRA Category 1 credits. Simply login using your username and password after downloading the free app.
- Unbiased critical evaluation of FDA-approved drugs, with a special emphasis on new drugs.
- Appraisal of new drugs for effectiveness, toxicity and cost, and discussion of possible alternatives.
- An occasional review of a new non-drug treatment or a new diagnostic aid.
Treatment Guidelines from The Medical Letter: Subscribers to Treatment Guidelines get full access to their paid subscription content with this free app and can take free CME/CE directly from their mobile device to earn up to 24 AMA PRA Category 1 credits. Simply login using your username and password after downloading the free app.
-Unbiased reviews of drug classes for treatment of some common disorders such as diabetes, hypertension, pain and insomnia.
-Quick reference charts for preferred drugs for treatment of a given disease.
-Recommendations for first choice and alternative drugs with assessments of the drugs’ effectiveness and safety.
-Adverse effects, drug interactions, and conclusions with clear recommendations to make smart choices easily.
Disease Index
Drug Index
Continuing Medical Education
Free Content – Available to non-subscribers and subscribers.
less
|
